Hemostemix Valuation
| HEM Stock | CAD 0.08 0.01 5.88% |
Hemostemix seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Hemostemix from evaluating the firm fundamentals such as Current Valuation of 15.05 M, number of shares shorted of 451, and Return On Asset of -3.49 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Hemostemix's valuation include:
Price Book 27.7582 | Enterprise Value 15.1 M | Enterprise Value Ebitda (4.37) |
Overvalued
Today
Please note that Hemostemix's price fluctuation is out of control at this time. Calculation of the real value of Hemostemix is based on 3 months time horizon. Increasing Hemostemix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Hemostemix stock is determined by what a typical buyer is willing to pay for full or partial control of Hemostemix. Since Hemostemix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hemostemix Stock. However, Hemostemix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.08 | Real 0.0662 | Hype 0.07 | Naive 0.0698 |
The intrinsic value of Hemostemix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hemostemix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hemostemix helps investors to forecast how Hemostemix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hemostemix more accurately as focusing exclusively on Hemostemix's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Hemostemix's intrinsic value based on its ongoing forecasts of Hemostemix's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Hemostemix's closest peers.
Hemostemix Cash |
|
Hemostemix Valuation Trend
Analysing the historical paterns of Hemostemix's enterprise value and its market capitalization is a good way to estimate and gauge the value of Hemostemix over time and is usually enough for investors to make rational market timing decisions.
Hemostemix Total Value Analysis
Hemostemix is currently estimated to have takeover price of 15.05 M with market capitalization of 9.92 M, debt of 4.32 M, and cash on hands of 49.36 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Hemostemix fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.05 M | 9.92 M | 4.32 M | 49.36 K |
Hemostemix Asset Utilization
One of the ways to look at asset utilization of Hemostemix is to check how much profit was generated for every dollar of assets it reports. Hemostemix retains a negative application of resources of -3.49 (percent), losing C$0.0349 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Hemostemix shows how discouraging it operates for each dollar spent on its resources.Hemostemix Ownership Allocation
Hemostemix has a total of 123.98 Million outstanding shares. Hemostemix retains 9.54 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Hemostemix Profitability Analysis
Net Loss for the year was (2.5 M) with profit before overhead, payroll, taxes, and interest of 0.About Hemostemix Valuation
Our relative valuation model uses a comparative analysis of Hemostemix. We calculate exposure to Hemostemix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Hemostemix's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | (223.00) | (234.15) |
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.